Feb 8 (Reuters) - Aptahem AB APTA.TE :
* APTAHEM REPORTS DELAY IN DELIVERY OF ITS DRUG PRODUCT
* APTAHEM ANTICIPATES THAT COMMENCEMENT OF PLANNED CLINICAL
STUDY
FOR APTA-1 WILL BE DELAYED.
* MANUFACTURE OF ITS DRUG PRODUCT HAS BEEN DELAYED AS A
RESULT OF
TECHNICAL CHALLENGES
* A NEED TO HAVE MORE DRUG PRODUCT MANUFACTURED WAS
ANNOUNCED IN A
PRESS RELEASE ON AUGUST 28, 2018 DURING PRECLINICAL TOXICOLOGY
PROGRAM.
* PLANNED CLINICAL STUDY WILL NOT START DURING Q3 THIS YEAR
AS
PREVIOUSLY COMMUNICATED.
* DELAY IS DUE TO A SERIES OF TECHNICAL DIFFICULTIES THAT
HAVE
BEEN ENCOUNTERED DURING CONTRACT MANUFACTURER'S PRODUCTION.
Source text for Eikon: ID:nWkr5vbK5M
Further company coverage: APTA.TE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))